EP Wealth Advisors LLC Has $88.61 Million Position in Johnson & Johnson $JNJ

EP Wealth Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 3.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 580,128 shares of the company’s stock after acquiring an additional 17,552 shares during the quarter. EP Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $88,614,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at $48,000. Vermillion & White Wealth Management Group LLC raised its stake in Johnson & Johnson by 66.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after acquiring an additional 150 shares in the last quarter. Gladwyn Financial Advisors Inc. acquired a new position in Johnson & Johnson during the second quarter worth $71,000. Finally, Pandora Wealth Inc. lifted its holdings in shares of Johnson & Johnson by 22.1% during the second quarter. Pandora Wealth Inc. now owns 476 shares of the company’s stock valued at $73,000 after acquiring an additional 86 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ opened at $211.65 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $509.93 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36. The company’s 50 day simple moving average is $196.09 and its 200-day simple moving average is $177.08. Johnson & Johnson has a one year low of $140.68 and a one year high of $212.27.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Finally, Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $206.65.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.